Revenue Showdown: Novo Nordisk A/S vs Merck & Co., Inc.

Pharma Giants' Revenue Race: Novo Nordisk vs Merck

__timestampMerck & Co., Inc.Novo Nordisk A/S
Wednesday, January 1, 20144223700000088806000000
Thursday, January 1, 201539498000000107927000000
Friday, January 1, 201639807000000111780000000
Sunday, January 1, 201740122000000111696000000
Monday, January 1, 201842294000000111831000000
Tuesday, January 1, 201946840000000122021000000
Wednesday, January 1, 202041518000000126946000000
Friday, January 1, 202148704000000140800000000
Saturday, January 1, 202259283000000176954000000
Sunday, January 1, 202360115000000232261000000
Monday, January 1, 2024290403000000
Loading chart...

Data in motion

Revenue Showdown: Novo Nordisk A/S vs Merck & Co., Inc.

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's success. Over the past decade, Novo Nordisk A/S and Merck & Co., Inc. have been at the forefront of this financial race. From 2014 to 2023, Novo Nordisk's revenue surged by approximately 161%, reaching a staggering $232 billion in 2023. In contrast, Merck's revenue grew by about 42%, peaking at $60 billion in the same year. This remarkable growth trajectory highlights Novo Nordisk's strategic advancements in diabetes care and other therapeutic areas. Meanwhile, Merck's steady growth reflects its robust portfolio in oncology and vaccines. As these giants continue to innovate, investors and industry watchers eagerly anticipate their next moves in this high-stakes revenue showdown.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025